Literature DB >> 20182414

Vitamin D: a pleiotropic hormone.

Annemieke Verstuyf1, Geert Carmeliet, Roger Bouillon, Chantal Mathieu.   

Abstract

The secosteroid hormone 1alpha,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) is the natural ligand for the vitamin D receptor, a member of the nuclear receptor superfamily. Upon binding of the ligand, the vitamin D receptor heterodimerizes with the retinoid X receptor and binds to vitamin D response elements in the promoter region of target genes to induce/repress their expression. The target genes that have been identified so far are heterogeneous in nature and reflect the great spectrum of biological activities of 1,25(OH)(2)D(3). Within the last two decades, the receptor has been shown to be present not only in classical target tissues such as bone, kidney, and intestine, but also in many other nonclassical tissues, for example, in the immune system (T and B cells, macrophages, and monocytes), in the reproductive system (uterus, testis, ovary, prostate, placenta, and mammary glands), in the endocrine system (pancreas, pituitary, thyroid, and adrenal cortex), in muscles (skeletal, smooth, and heart muscles), and in brain, skin, and liver. Besides the almost universal presence of vitamin D receptors, different cell types (for example, keratinocytes, monocytes, bone, placenta) are capable of metabolizing 25-hydroxyvitamin D(3) to 1,25(OH)(2)D(3) by the enzyme 25(OH)D(3)-1alpha-hydroxylase, encoded by CYP27B1. The combined presence of CYP27B1 and the specific receptor in several tissues introduced the idea of a paracrine/autocrine role for 1,25(OH)(2)D(3). Moreover, it has been demonstrated that 1,25(OH)(2)D(3) can induce differentiation and inhibit proliferation of normal and malignant cells. Moreover, vitamin D deficiency is associated with an increased risk for nearly all major human diseases such as cancer, autoimmune diseases, cardiovascular, and metabolic diseases. In addition to the treatment of bone disorders with 1,25(OH)(2)D(3), these newly discovered functions open perspectives for the use of 1,25(OH)(2)D(3) as an immune modulator (for example, for the treatment of autoimmune diseases or prevention of graft rejection), inhibitor of cell proliferation, and inducer of cell differentiation (cancer).

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20182414     DOI: 10.1038/ki.2010.17

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  103 in total

Review 1.  Can vitamin D slow down the progression of chronic kidney disease?

Authors:  Rukshana Shroff; Mandy Wan; Lesley Rees
Journal:  Pediatr Nephrol       Date:  2011-12-10       Impact factor: 3.714

2.  VDR haploinsufficiency impacts body composition and skeletal acquisition in a gender-specific manner.

Authors:  Francisco J A de Paula; Ingrid Dick-de-Paula; Sheila Bornstein; Bahman Rostama; Phuong Le; Sutada Lotinun; Roland Baron; Clifford J Rosen
Journal:  Calcif Tissue Int       Date:  2011-06-03       Impact factor: 4.333

Review 3.  The dualistic role of vitamin D in vascular calcifications.

Authors:  M Shawkat Razzaque
Journal:  Kidney Int       Date:  2010-10-20       Impact factor: 10.612

4.  Serum 25-hydroxyvitamin-D and nonalcoholic fatty liver disease: Does race/ethnicity matter? Findings from the MESA cohort.

Authors:  Samar R El Khoudary; Saad Samargandy; Irfan Zeb; Temitope Foster; Ian H de Boer; Dong Li; Matthew J Budoff
Journal:  Nutr Metab Cardiovasc Dis       Date:  2019-09-10       Impact factor: 4.222

Review 5.  Vitamin d and physical performance.

Authors:  Daniel S Moran; James P McClung; Tal Kohen; Harris R Lieberman
Journal:  Sports Med       Date:  2013-07       Impact factor: 11.136

6.  Associations of total and free 25OHD and 1,25(OH)2D with serum markers of inflammation in older men.

Authors:  P Srikanth; R F Chun; M Hewison; J S Adams; R Bouillon; D Vanderschueren; N Lane; P M Cawthon; T Dam; E Barrett-Connor; L B Daniels; J M Shikany; M L Stefanick; J A Cauley; E S Orwoll; C M Nielson
Journal:  Osteoporos Int       Date:  2016-02-23       Impact factor: 4.507

7.  Impact of vitamin D supplementation on inflammatory markers in African Americans: results of a four-arm, randomized, placebo-controlled trial.

Authors:  Paulette D Chandler; Jamil B Scott; Bettina F Drake; Kimmie Ng; Joann E Manson; Nader Rifai; Andrew T Chan; Gary G Bennett; Bruce W Hollis; Edward L Giovannucci; Karen M Emmons; Charles S Fuchs
Journal:  Cancer Prev Res (Phila)       Date:  2013-12-10

8.  Serum Vitamin D Level at ICU Admission and Mortality.

Authors:  Hakan Korkut Atalan; Bülent Güçyetmez
Journal:  Turk J Anaesthesiol Reanim       Date:  2017-08-01

Review 9.  Vitamin D Status and Supplementation in the Critically Ill.

Authors:  T J McKinney; Jayshil J Patel; Matthew V Benns; Nicholas A Nash; Keith R Miller
Journal:  Curr Gastroenterol Rep       Date:  2016-04

10.  Compromised Activation of Vitamin D After Elective Surgery: A Prospective Pilot Study.

Authors:  Martin Blomberg Jensen; Henrik Husted; Poul Jannik Bjerrum; Anders Juul; Henrik Kehlet
Journal:  JBMR Plus       Date:  2018-05-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.